Nicotine metabolism and CYP2A6 allele frequencies in Koreans.

CYP2A6 is a major catalyst of nicotine metabolism to cotinine. Previously, we demonstrated that the interindividual difference in nicotine metabolism is related to a genetic polymorphism of the CYP2A6 gene in Japanese. To clarify the ethnic differences in nicotine metabolism and frequencies of CYP2A6 alleles, we studied nicotine metabolism and the CYP2A6 genotype in 209 Koreans. The cotinine/nicotine ratio of the plasma concentration 2 h after chewing one piece of nicotine gum was calculated as an index of nicotine metabolism. The genotypes of CYP2A6 gene (CYP2A6*1A, CYP2A6*1B, CYP2A6*2, CYP2A6*3, CYP2A6*4 and CYP2A6*5) were determined by polymerase chain reaction (PCR)-restriction fragment length polymorphism or allele specific (AS)-PCR. There were ethnic differences in the allele frequencies of CYP2A6*1A, CYP2A6*1B, CYP2A6*4 and CYP2A6*5 between Koreans (45.7%, 42.8%, 11.0% and 0.5%, respectively) and Japanese (42.4%, 37.5%, 20.1% and 0%, respectively, our previous data). Similar to the Japanese, no CYP2A6*2 and CYP2A6*3 alleles were found in Koreans. The homozygotes of the CYP2A6*4 allele (four subjects) were completely deficient in cotinine formation, being consistent with the data among Japanese. The heterozygotes of CYP2A6*4 tended to possess a lower metabolic ratio (CYP2A6*1A/CYP2A6*4, 4.79 +/- 3.17; CYP2A6*1B/CYP2A6*4, 7.43 +/- 4.97) than that in subjects without the allele (CYP2A6*1A/CYP2A6*1A, 7.42 +/- 6.56; CYP2A6*1A/CYP2A6*1B, 9.85 +/- 16.12; CYP2A6*1B/CYP2A6*1B, 11.33 +/- 9.33). The subjects who possess the CYP2A6*1B allele appeared to show higher capabilities of cotinine formation. It was confirmed that the interindividual difference in nicotine metabolism was closely related to the genetic polymorphism of CYP2A6. The probit plot of the metabolic ratios in Koreans (8.73 +/- 11.88) was shifted to a higher ratio than that in the Japanese (3.78 +/- 3.09). In each genotype group, the Korean subjects revealed significantly higher metabolic ratios than the Japanese subjects. The ethnic difference in cotinine formation might be due to environmental and/or diet factors as well as genetic factors.

[1]  F. Gonzalez,et al.  The CYP2A3 gene product catalyzes coumarin 7-hydroxylation in human liver microsomes. , 1990, Biochemistry.

[2]  J. Idle,et al.  Poor metabolisers of nicotine and CYP2D6 polymorphism , 1994, The Lancet.

[3]  B. Lake,et al.  Expression and alternative splicing of the cytochrome P-450 CYP2A7. , 1995, The Biochemical journal.

[4]  O Pelkonen,et al.  A genetic polymorphism in coumarin 7-hydroxylation: sequence of the human CYP2A genes and identification of variant CYP2A6 alleles. , 1995, American journal of human genetics.

[5]  P. Fernández-Salguero,et al.  The CYP2A gene subfamily: species differences, regulation, catalytic activities and role in chemical carcinogenesis. , 1995, Pharmacogenetics.

[6]  N. Benowitz,et al.  Deficient C‐oxidation of nicotine , 1995, Clinical pharmacology and therapeutics.

[7]  D W Nebert,et al.  P450 superfamily: update on new sequences, gene mapping, accession numbers and nomenclature. , 1996, Pharmacogenetics.

[8]  Y. Funae,et al.  Role of human cytochrome P4502A6 in C-oxidation of nicotine. , 1996, Drug metabolism and disposition: the biological fate of chemicals.

[9]  G. Wilkinson,et al.  The effects of diet, aging and disease-states on presystemic elimination and oral drug bioavailability in humans. , 1997, Advanced drug delivery reviews.

[10]  G. Giovino,et al.  Racial and Ethnic Differences in Serum Cotinine Levels of Cigarette Smokers , 1998 .

[11]  J. Stengård,et al.  Genotyping of human cytochrome P450 2A6 (CYP2A6), a nicotine C‐oxidase , 1998, FEBS letters.

[12]  E. Perez-stable,et al.  Nicotine metabolism and intake in black and white smokers. , 1998, JAMA.

[13]  G. Giovino,et al.  Racial and ethnic differences in serum cotinine levels of cigarette smokers: Third National Health and Nutrition Examination Survey, 1988-1991. , 1998, JAMA.

[14]  T. Kamataki,et al.  A new CYP2A6 gene deletion responsible for the in vivo polymorphic metabolism of (+)-cis-3,5-dimethyl-2-(3-pyridyl)thiazolidin-4-one hydrochloride in humans. , 1999, The Journal of pharmacology and experimental therapeutics.

[15]  K. Kitagawa,et al.  The significance of the homozygous CYP2A6 deletion on nicotine metabolism: a new genotyping method of CYP2A6 using a single PCR-RFLP. , 1999, Biochemical and biophysical research communications.

[16]  M. Ingelman-Sundberg,et al.  Characterisation and PCR‐based detection of a CYP2A6 gene deletion found at a high frequency in a Chinese population , 1999, FEBS letters.

[17]  O Pelkonen,et al.  Identification and characterisation of novel polymorphisms in the CYP2A locus: implications for nicotine metabolism , 1999, FEBS letters.

[18]  B. Green,et al.  Low frequency of CYP2A6 gene polymorphism as revealed by a one-step polymerase chain reaction method. , 1999, Pharmacogenetics.

[19]  T. Kamataki,et al.  Homologous unequal cross-over within the human CYP2A gene cluster as a mechanism for the deletion of the entire CYP2A6 gene associated with the poor metabolizer phenotype. , 1999, Journal of biochemistry.

[20]  Hiroshi Yamamoto,et al.  Deficient cotinine formation from nicotine is attributed to the whole deletion of the CYP2A6 gene in humans , 2000, Clinical pharmacology and therapeutics.

[21]  H. Yamazaki,et al.  CYP2A6 genetic polymorphisms and liver microsomal coumarin and nicotine oxidation activities in Japanese and Caucasians , 2000, Archives of Toxicology.

[22]  R. Tyndale,et al.  Duplications and defects in the CYP2A6 gene: identification, genotyping, and in vivo effects on smoking. , 2000, Molecular pharmacology.

[23]  O. Pelkonen,et al.  CYP2A6: a human coumarin 7-hydroxylase. , 2000, Toxicology.

[24]  M. Nakajima,et al.  Improved highly sensitive method for determination of nicotine and cotinine in human plasma by high-performance liquid chromatography. , 2000, Journal of chromatography. B, Biomedical sciences and applications.

[25]  W. Legrum,et al.  Genetic polymorphism of CYP2A6 in the German population. , 2000, Toxicology.

[26]  Hiroshi Yamamoto,et al.  Relationship between interindividual differences in nicotine metabolism and CYP2A6 genetic polymorphism in humans , 2001, Clinical pharmacology and therapeutics.